PDS Biotechnology Corporation

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company headquartered in Princeton, New Jersey. The company currently employs 31 individuals and reports annual revenue of $3 million. PDS Biotech specializes in the development and commercialization of therapies utilizing the Versamune® platform. This platform is a T-cell activating technology designed to leverage the body's natural immune system to combat both cancer and infectious diseases. What sets PDS Biotech apart is its innovative Versamune® platform, which has the potential to revolutionize the treatment of various diseases by effectively activating the body's own immune response. This targeted approach to therapy offers a promising avenue for developing innovative and effective treatments. For further information about PDS Biotechnology Corporation and its groundbreaking work, please visit their website at pdsbiotech.com.

PDS Biotechnology is a biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company's primary focus is on the healthcare, pharmaceuticals, biotechnology, and research and development industries. PDS Biotechnology operates from its location at 303A College Road East, Princeton, NJ 08540. The company's proprietary Versamune® and PDS01ADC platforms are designed to enhance the immune system's ability to target and fight cancer. PDS Biotech has a growing pipeline of immunotherapies for various cancers. PDS Biotechnology is committed to advancing its technologies through strategic partnerships. The company's leadership team includes Frank Bedu-Addo, Ph.D., as Chief Executive Officer and Director; Stephan Toutain as Chief Operating Officer; Lars Boesgaard as Chief Financial Officer; Gregory Conn, Ph.D., as Chief Scientific Officer; Kirk Shepard, M.D., as Chief Medical Officer; Spencer Brown as Senior Vice-President, General Counsel, Corporate Secretary and Compliance Officer; Rory Cullinane as Vice President of Quality; and David Schaaf, M.D., as Vice President of Medical Affairs. PDS Biotechnology's competitive advantages include its proprietary Versamune® and PDS01ADC platforms, a strong leadership team with extensive industry experience, a growing pipeline of immunotherapies for various cancers, and strategic partnerships with renowned research institutions and pharmaceutical companies. The company's values include harnessing the power of T cells to address devastating illnesses, a commitment to developing novel investigational immunotherapies, and a focus on improving patient outcomes and quality of life. PDS Biotechnology can be contacted by phone at (800) 208-3343, +1 (917) 797-7904, (617) 308-4306, or (908) 344-5494. Inquiries can also be sent via email to [email protected], [email protected], [email protected], or [email protected].